FARMORUBICIN
 |
|
|
Package(a):
VIAL (PFS - Preservation Free Solution. Ready to use): 1 x 10 mg/5 ml/vial.
Dosage(a):
I.V.: As single agent. 60-90 mg/m² body area as I.V. bolus over 3-5 minutes. Repeat at 21 day intervals depending on patient's hematomedullar status. Intravesical for superficial bladder carcinoma: See prescribing information for full details.
Prescribing Restrictions:
Package(b):
VIAL (PFS - Preservation Free Solution. Ready to use): 1 x 50 mg/25 ml/vial.
This package has been discontinued.
Dosage(b):
I.V.: As single agent. 60-90 mg/m² body area as I.V. bolus over 3-5 minutes. Repeat at 21 day intervals depending on patient''s hematomedullar status. Intravesical for superficial bladder carcinoma: See prescribing information for full details.
Prescribing Restrictions: None
Indications:
Wide spectrum neoplastic diseases, including breast, ovarian, gastric, soft tissue carcinoma, in high doses for lung carcinoma, bladder carcinoma including superficial bladder carcinoma.
Contra-Indications:
Marked mylosuppression, patients previously treated with other antitumor agents/radio-therapy, maximum cumulative doses of other anthracyclines, history of cardiac impairment. Rapid dissolution: hypersensitivity to hydroxybenzoates.
Special Precautions:
See prescribing information for full details.
Side Effects:
See prescribing information for full details.
Drug Interactions:
See prescribing information for full details.
